GW Pharmaceuticals to Present at the Cowen 40th Annual Healthcare Conference
February 24 2020 - 7:00AM
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the
Group), a world leader in the science, development, and
commercialization of cannabinoid prescription medicines, today
announced that Justin Gover, GW’s Chief Executive Officer, will
present a business update at the Cowen 40th Annual Healthcare
Conference on Tuesday, March 3rd, 2020 at 8:40 am EST.
Live audio webcasts of the presentation and
breakout session will be available through GW’s corporate website
at www.gwpharm.com on the Investors section under Events &
Presentations. A replay will be available for each soon after the
live presentation.
About GW Pharmaceuticals plc and
Greenwich Biosciences, Inc.Founded in 1998, GW is a
biopharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform in a broad range of disease areas. GW’s lead
product, EPIDIOLEX (cannabidiol) oral solution is commercialized in
the U.S. by its U.S. subsidiary Greenwich Biosciences for the
treatment of seizures associated with Lennox-Gastaut syndrome or
Dravet syndrome in patients two years of age or older. This product
has received approval in the European Union under the tradename
EPIDYOLEX. The Company expects to expand the indication of
EPIDIOLEX to include seizures associated with Tuberous Sclerosis
Complex, for which it has reported positive Phase 3 data, and is
carrying out a Phase 3 trial in Rett syndrome. GW commercialized
the world’s first plant-derived cannabinoid prescription drug,
Sativex® (nabiximols), which is approved for the treatment of
spasticity due to multiple sclerosis in numerous countries outside
the United States and for which the Company is now advancing a late
stage program in order to seek FDA approval. The Company has a deep
pipeline of additional cannabinoid product candidates which
includes compounds in Phase 1 and 2 trials for epilepsy, autism,
and schizophrenia. For further information, please visit
www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc |
|
Stephen Schultz, VP Investor Relations (U.S.) |
917 280 2424 / 401 500 6570 |
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Jul 2023 to Jul 2024